Advanced Accelerator Application SA(ADR) Share Price

Equities

End-of-day quote Nasdaq Other stock markets
-	-

2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE
2017	Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	RE

Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	03/17/03	RE
Advanced Accelerator Application : Novartis to buy French cancer specialist AAA for $3.9 billion	30/17/30	RE
Advanced Accelerator Application : Novartis to buy France's Advanced Accelerator for $3.9 billion	30/17/30	RE

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications	03/18/03	GL
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer	12/18/12	GL
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer	02/18/02	GL
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors	26/18/26	GL
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer	22/18/22	GL

Novartis : Le conseil d'administration d'AAA recommande l'offre de 3,9 mds de dollars de Novartis	06/17/06
Advanced Accelerator Application : Novartis offre 3,9 milliards de dollars pour le français Advanced Accelerator	30/17/30
WDH/Novartis will US-Unternehmen Advanced Accelerator Applications übernehmen	30/17/30
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	30/17/30
Novartis : compte acquérir Advanced Accelerator Applications pour 3,9 mds de dollars	30/17/30

Managers	Title	Age	Since
Caio Kugelmas DFI	Director of Finance/CFO	-	-
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	01/19/01
Ute Simon CTO	Chief Tech/Sci/R&D Officer	-	01/20/01

Members of the board	Title	Age	Since
Frédéric Collet BRD	Director/Board Member	-	01/18/01
Jessica Toepfer BRD	Director/Board Member	-	01/18/01
Sidonie Roswitha Golombowski-Daffner CHM	Chairman	-	01/19/01

Sector

	1st Jan change	Capi.
MERCK KGAA	+3.37%	69.25B
KYOWA KIRIN CO. LTD.	+12.55%	9B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+5.23%	3.9B
INDIVIOR PLC	+19.92%	2.45B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B